{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T22:34:03Z","timestamp":1794090843470,"version":"4.8.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Microbiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Finland faced an outbreak of highly pathogenic clade 2.3.4.4b A(H5N1) avian influenza in 2023, which spread from wild birds to fur farms. Vaccinations of at-risk individuals began in June 2024 using the MF59-adjuvanted inactivated A(H5N8) vaccine (Seqirus; A\/Astrakhan\/3212\/2020, clade 2.3.4.4b). Here, in an observational study, we assessed vaccine-induced immune responses in occupational at-risk individuals participating in the phase IV trial, including virus-specific antibody (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200939 individuals) and T-cell (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200918 individuals) responses. Vaccination elicited functional antibodies against the vaccine virus and two heterologous clade 2.3.4.4b strains associated with outbreaks on Finnish fur farms and dairy cattle in the United States. Among previously unvaccinated individuals, seroprotection rates against the vaccine virus were 83% (95% CI 70\u201397%) by microneutralization assay (titre \u226520) and 97% (90\u2013100%) by haemagglutination inhibition assay (titre \u226540). In those previously vaccinated against avian influenza, a single dose induced seroprotection. A(H5N8)-specific memory CD4\n                    <jats:sup>+<\/jats:sup>\n                    T-cell responses were detectable, with ~5-fold increase in IFN\u03b3 secretion after two doses. These results demonstrate that the vaccine probably provides cross-protection against circulating H5 clade 2.3.4.4b viruses. EU Clinical Trial Number 2023-509178-44-00.\n                  <\/jats:p>","DOI":"10.1038\/s41564-025-02183-5","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T10:02:50Z","timestamp":1764928970000},"page":"155-168","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Influenza A(H5N8) vaccine induces humoral and cell-mediated immunity against highly pathogenic avian influenza clade 2.3.4.4b A(H5N1) viruses in at-risk individuals"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1570-4325","authenticated-orcid":false,"given":"Oona","family":"Liedes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arttu","family":"Reinholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Ekstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anu","family":"Haveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Solastie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saimi","family":"Vara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3151-3725","authenticated-orcid":false,"given":"Willemijn F.","family":"Rijnink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo M.","family":"Bestebroer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0240-9312","authenticated-orcid":false,"given":"Mathilde","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2817-0127","authenticated-orcid":false,"given":"Rory D.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinja","family":"Jalkanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Lindh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niina","family":"Ikonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2209-5966","authenticated-orcid":false,"given":"Alba","family":"Grifoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7013-2250","authenticated-orcid":false,"given":"Alessandro","family":"Sette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terhi","family":"Laaksonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riikka","family":"Holopainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Kakkola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maija","family":"Lappalainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritva K.","family":"Syrj\u00e4nen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pekka","family":"Kolehmainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilkka","family":"Julkunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Nohynek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9375-4327","authenticated-orcid":false,"given":"Merit","family":"Melin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"2183_CR1","doi-asserted-by":"publisher","first-page":"e9191","DOI":"10.2903\/j.efsa.2025.9191","volume":"23","author":"EFSA Panel on Animal Health and Animal Welfare (AHAW) et al.","year":"2025","unstructured":"EFSA Panel on Animal Health and Animal Welfare (AHAW) et al. Preparedness, prevention and control related to zoonotic avian influenza. EFSA J. 23, e9191 (2025).","journal-title":"EFSA J."},{"key":"2183_CR2","doi-asserted-by":"publisher","first-page":"2300400","DOI":"10.2807\/1560-7917.ES.2023.28.31.2300400","volume":"28","author":"E Lindh","year":"2023","unstructured":"Lindh, E. et al. Highly pathogenic avian influenza A(H5N1) virus infection on multiple fur farms in the South and Central Ostrobothnia regions of Finland, July 2023. Eurosurveillance 28, 2300400 (2023).","journal-title":"Eurosurveillance"},{"key":"2183_CR3","unstructured":"El\u00e4intaudit Suomessa 2023 Finnish Food Authority publications 5\/2024 (Finnish Food Authority, 2024)."},{"key":"2183_CR4","doi-asserted-by":"publisher","first-page":"2400063","DOI":"10.2807\/1560-7917.ES.2024.29.25.2400063","volume":"29","author":"L Kareinen","year":"2024","unstructured":"Kareinen, L. et al. Highly pathogenic avian influenza A(H5N1) virus infections on fur farms connected to mass mortalities of black-headed gulls, Finland, July to October 2023. Eurosurveillance 29, 2400063 (2024).","journal-title":"Eurosurveillance"},{"key":"2183_CR5","first-page":"e9197","volume":"23","author":"EFSA Authority (EFSA) et al.","year":"2025","unstructured":"EFSA Authority (EFSA) et al. Avian influenza annual report 2023. EFSA J. 23, e9197 (2025).","journal-title":"EFSA J."},{"key":"2183_CR6","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41586-024-07849-4","volume":"634","author":"LC Caserta","year":"2024","unstructured":"Caserta, L. C. et al. Spillover of highly pathogenic avian influenza H5N1 virus to dairy cattle. Nature 634, 669\u2013676 (2024).","journal-title":"Nature"},{"key":"2183_CR7","unstructured":"H5 Bird Flu: Current Situation (Centers of Disease Control and Prevention (CDC), accessed 29 May 2025); https:\/\/www.cdc.gov\/bird-flu\/situation-summary\/index.html"},{"key":"2183_CR8","unstructured":"Cumulative Number of Confirmed Human Cases for Avian Influenza A(H5N1) Reported to WHO, 2003\u20132025 (WHO, 2025)."},{"key":"2183_CR9","unstructured":"Genetic Sequences of Highly Pathogenic Avian Influenza A(H5N1) Viruses Identified in a Person in Louisiana (Centers of Disease Control and Prevention (CDC), 2025)."},{"key":"2183_CR10","doi-asserted-by":"publisher","unstructured":"Jassem, A. N. et al. Critical illness in an adolescent with influenza A(H5N1) virus infection. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMc2415890 (2024).","DOI":"10.1056\/NEJMc2415890"},{"key":"2183_CR11","doi-asserted-by":"publisher","first-page":"2400383","DOI":"10.2807\/1560-7917.ES.2024.29.25.2400383","volume":"29","author":"H Nohynek","year":"2024","unstructured":"Nohynek, H. & Helve, O. M. One health, many interpretations: vaccinating risk groups against H5 avian influenza in Finland. Eur. Surveill. 29, 2400383 (2024).","journal-title":"Eur. Surveill."},{"key":"2183_CR12","unstructured":"Virkku, A. et al. Avian Influenza Vaccinations in Finland: Rationale for the Recommendation and the Target Groups of the Vaccinations Discussion Paper 43\/2024 (Finnish Institute for Health and Welfare (THL), 2024)."},{"key":"2183_CR13","unstructured":"Zoonotic Influenza Vaccine Seqirus (European Medicines Agency (EMA), 2023)."},{"key":"2183_CR14","unstructured":"Union Register of Medicinal Products (European Commission, accessed 29 May 2023); https:\/\/ec.europa.eu\/health\/documents\/community-register\/html\/h1761.htm"},{"key":"2183_CR15","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.3390\/vaccines9121465","volume":"9","author":"A Kok","year":"2021","unstructured":"Kok, A., Fouchier, R. A. M. & Richard, M. Cross-reactivity conferred by homologous and heterologous prime\u2013boost A\/H5 influenza vaccination strategies in humans: a literature review. Vaccines 9, 1465 (2021).","journal-title":"Vaccines"},{"key":"2183_CR16","unstructured":"Summary of Product Characteristics. Zoonotic Influenza Vaccine Seqirus H5N8 (European Medicines Agency (EMA), 2023)."},{"key":"2183_CR17","doi-asserted-by":"publisher","first-page":"6284","DOI":"10.1016\/j.vaccine.2009.01.040","volume":"27","author":"TF Schwarz","year":"2009","unstructured":"Schwarz, T. F. et al. Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine 27, 6284\u20136290 (2009).","journal-title":"Vaccine"},{"key":"2183_CR18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1750-2659.2012.00349.x","volume":"7","author":"P Gillard","year":"2013","unstructured":"Gillard, P. et al. An assessment of prime\u2013boost vaccination schedules with AS03A-adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults. Influenza Other Respir. Viruses 7, 55\u201365 (2013).","journal-title":"Influenza Other Respir. Viruses"},{"key":"2183_CR19","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41541-019-0114-8","volume":"4","author":"MZ Levine","year":"2019","unstructured":"Levine, M. Z. et al. Heterologous prime\u2013boost with A(H5N1) pandemic influenza vaccines induces broader cross-clade antibody responses than homologous prime\u2013boost. npj Vaccines 4, 22 (2019).","journal-title":"npj Vaccines"},{"key":"2183_CR20","doi-asserted-by":"publisher","first-page":"ofu091","DOI":"10.1093\/ofid\/ofu091","volume":"1","author":"WH Chen","year":"2014","unstructured":"Chen, W. H. et al. Safety, reactogenicity, and immunogenicity of inactivated monovalent influenza A(H5N1) virus vaccine administered with or without AS03 adjuvant. Open Forum Infect. Dis. 1, ofu091 (2014).","journal-title":"Open Forum Infect. Dis."},{"key":"2183_CR21","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.virusres.2004.02.019","volume":"103","author":"I Stephenson","year":"2004","unstructured":"Stephenson, I., Wood, J. M., Nicholson, K. G., Charlett, A. & Zambon, M. C. Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A\/Duck\/Singapore\/97 vaccine. Virus Res. 103, 91\u201395 (2004).","journal-title":"Virus Res."},{"key":"2183_CR22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jviromet.2008.06.016","volume":"153","author":"N Jia","year":"2008","unstructured":"Jia, N. et al. Increased sensitivity for detecting avian influenza-specific antibodies by a modified hemagglutination inhibition assay using horse erythrocytes. J. Virol. Methods 153, 43\u201348 (2008).","journal-title":"J. Virol. Methods"},{"key":"2183_CR23","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.3201\/eid1508.081754","volume":"15","author":"I Stephenson","year":"2009","unstructured":"Stephenson, I. et al. Reproducibility of serologic assays for influenza virus A (H5N1). Emerg. Infect. Dis. 15, 1250\u20131259 (2009).","journal-title":"Emerg. Infect. Dis."},{"key":"2183_CR24","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jviromet.2010.11.024","volume":"171","author":"S Grund","year":"2011","unstructured":"Grund, S., Adams, O., W\u00e4hlisch, S. & Schweiger, B. Comparison of hemagglutination inhibition assay, an ELISA-based micro-neutralization assay and colorimetric microneutralization assay to detect antibody responses to vaccination against influenza A H1N1 2009 virus. J. Virol. Methods 171, 369\u2013373 (2011).","journal-title":"J. Virol. Methods"},{"key":"2183_CR25","doi-asserted-by":"publisher","first-page":"e0131531","DOI":"10.1371\/journal.pone.0131531","volume":"10","author":"CP Verschoor","year":"2015","unstructured":"Verschoor, C. P. et al. Microneutralization assay titres correlate with protection against seasonal influenza H1N1 and H3N2 in children. PLoS ONE 10, e0131531 (2015).","journal-title":"PLoS ONE"},{"key":"2183_CR26","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1016\/j.vaccine.2019.03.078","volume":"37","author":"A Haveri","year":"2019","unstructured":"Haveri, A. et al. Seasonal influenza vaccines induced high levels of neutralizing cross-reactive antibody responses against different genetic group influenza A(H1N1)pdm09 viruses. Vaccine 37, 2731\u20132740 (2019).","journal-title":"Vaccine"},{"key":"2183_CR27","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1038\/s41591-024-03189-y","volume":"30","author":"S Khurana","year":"2024","unstructured":"Khurana, S. et al. Licensed H5N1 vaccines generate cross-neutralizing antibodies against highly pathogenic H5N1 clade 2.3.4.4b influenza virus. Nat. Med. 30, 2771\u20132776 (2024).","journal-title":"Nat. Med."},{"key":"2183_CR28","doi-asserted-by":"publisher","first-page":"7962","DOI":"10.1073\/pnas.0903181106","volume":"106","author":"G Galli","year":"2009","unstructured":"Galli, G. et al. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc. Natl Acad. Sci. USA 106, 7962\u20137967 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2183_CR29","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.vaccine.2020.11.041","volume":"39","author":"A Haveri","year":"2021","unstructured":"Haveri, A., Ikonen, N., Savolainen-Kopra, C. & Julkunen, I. Long-lasting heterologous antibody responses after sequential vaccination with A\/Indonesia\/5\/2005 and A\/Vietnam\/1203\/2004 pre-pandemic influenza A(H5N1) virus vaccines. Vaccine 39, 402\u2013411 (2021).","journal-title":"Vaccine"},{"key":"2183_CR30","first-page":"572","volume":"104","author":"T Francis","year":"1960","unstructured":"Francis, T. On the doctrine of original antigenic sin. Proc. Am. Philos. Soc. 104, 572\u2013578 (1960).","journal-title":"Proc. Am. Philos. Soc."},{"key":"2183_CR31","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.it.2017.08.003","volume":"39","author":"C Henry","year":"2018","unstructured":"Henry, C., Palm, A.-K. E., Krammer, F. & Wilson, P. C. From original antigenic sin to the universal influenza virus vaccine. Trends Immunol. 39, 70\u201379 (2018).","journal-title":"Trends Immunol."},{"key":"2183_CR32","doi-asserted-by":"crossref","unstructured":"Almeida, N. D. et al. The effect of dose-interval on antibody response to mRNA COVID-19 vaccines: a prospective cohort study. Front. Immunol. 15, 1330549 (2024).","DOI":"10.3389\/fimmu.2024.1330549"},{"key":"2183_CR33","doi-asserted-by":"publisher","first-page":"ofae689","DOI":"10.1093\/ofid\/ofae689","volume":"11","author":"D Follmann","year":"2024","unstructured":"Follmann, D. et al. Who to boost when: the effect of age and dosing interval on delta and omicron COVID-19 incidence in the open-label phase of the COVE trial. Open Forum Infect. Dis. 11, ofae689 (2024).","journal-title":"Open Forum Infect. Dis."},{"key":"2183_CR34","doi-asserted-by":"publisher","first-page":"5644","DOI":"10.1016\/j.vaccine.2017.08.061","volume":"35","author":"S Tan","year":"2017","unstructured":"Tan, S. et al. Hemagglutinin-specific CD4+ T-cell responses following 2009-pH1N1 inactivated split-vaccine inoculation in humans. Vaccine 35, 5644\u20135652 (2017).","journal-title":"Vaccine"},{"key":"2183_CR35","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1093\/jpids\/piae095","volume":"13","author":"I Shannon","year":"2024","unstructured":"Shannon, I., Huertas, N., White, C. L., Yang, H. & Nayak, J. L. Development of influenza-specific CD4 T cell-mediated immunity in children following inactivated influenza vaccination. J. Pediatr. Infect. Dis. Soc. 13, 505\u2013512 (2024).","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"2183_CR36","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.4049\/jimmunol.1302503","volume":"193","author":"RS Herati","year":"2014","unstructured":"Herati, R. S. et al. Circulating CXCR5\u207aPD-1\u207a response predicts influenza vaccine antibody responses in young adults but not elderly adults. J. Immunol. 193, 3528\u20133537 (2014).","journal-title":"J. Immunol."},{"key":"2183_CR37","first-page":"740","volume":"215","author":"M-C Trieu","year":"2017","unstructured":"Trieu, M.-C. et al. Long-term maintenance of the influenza-specific cross-reactive memory CD4\u207a T-cell responses following repeated annual influenza vaccination. J. Infect. Dis. 215, 740\u2013749 (2017).","journal-title":"J. Infect. Dis."},{"key":"2183_CR38","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1093\/infdis\/jir436","volume":"204","author":"DF Hoft","year":"2011","unstructured":"Hoft, D. F. et al. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-Cell responses in young children. J. Infect. Dis. 204, 845\u2013853 (2011).","journal-title":"J. Infect. Dis."},{"key":"2183_CR39","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.vaccine.2006.08.036","volume":"25","author":"JHCM Kreijtz","year":"2007","unstructured":"Kreijtz, J. H. C. M. et al. Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice. Vaccine 25, 612\u2013620 (2007).","journal-title":"Vaccine"},{"key":"2183_CR40","doi-asserted-by":"publisher","first-page":"4983","DOI":"10.1016\/j.vaccine.2009.05.079","volume":"27","author":"JHCM Kreijtz","year":"2009","unstructured":"Kreijtz, J. H. C. M. et al. Infection of mice with a human influenza A\/H3N2 virus induces protective immunity against lethal infection with influenza A\/H5N1 virus. Vaccine 27, 4983\u20134989 (2009).","journal-title":"Vaccine"},{"key":"2183_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002381","volume":"7","author":"JT Weinfurter","year":"2011","unstructured":"Weinfurter, J. T. et al. Cross-reactive T cells are involved in rapid clearance of 2009 pandemic H1N1 influenza virus in nonhuman primates. PLoS Pathog. 7, e1002381 (2011).","journal-title":"PLoS Pathog."},{"key":"2183_CR42","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/nm.3350","volume":"19","author":"S Sridhar","year":"2013","unstructured":"Sridhar, S. et al. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat. Med. 19, 1305\u20131312 (2013).","journal-title":"Nat. Med."},{"key":"2183_CR43","doi-asserted-by":"publisher","first-page":"939860","DOI":"10.1155\/2011\/939860","volume":"2011","author":"MLB Hillaire","year":"2011","unstructured":"Hillaire, M. L. B., Osterhaus, A. D. M. E. & Rimmelzwaan, G. F. Induction of virus-specific cytotoxic T Lymphocytes as a basis for the development of broadly protective influenza vaccines. Biomed. Res. Int. 2011, 939860 (2011).","journal-title":"Biomed. Res. Int."},{"key":"2183_CR44","first-page":"e03479","volume":"16","author":"J Sidney","year":"2024","unstructured":"Sidney, J. et al. Targets of influenza human T-cell response are mostly conserved in H5N1. mBio 16, e03479-24 (2024).","journal-title":"mBio"},{"key":"2183_CR45","doi-asserted-by":"crossref","unstructured":"Mellis, A. M. Serologic evidence of recent infection with highly pathogenic avian influenza A(H5) virus among dairy workers \u2013 Michigan and Colorado, June\u2013August 2024. MMWR Morb. Mortal. Wkly Rep. 73, 1004\u20131009 (2024).","DOI":"10.15585\/mmwr.mm7344a3"},{"key":"2183_CR46","unstructured":"Health Alert Network (HAN) \u2013 00506: Highly Pathogenic Avian Influenza A(H5N1) Virus: Identification of Human Infection and Recommendations for Investigations and Response (Centers for Disease Control and Prevention (CDC), 2025)."},{"key":"2183_CR47","unstructured":"Genetic and Antigenic Characteristics of Clade 2.3.4.4b A(H5N1) Viruses Identified in Dairy Cattle in the United States of America (WHO, 2025)."},{"key":"2183_CR48","unstructured":"European Medicines Agency (EMA). Search for Clinical Trials https:\/\/euclinicaltrials.eu\/search-for-clinical-trials\/?lang=en&EUCT\u2009=\u20092023-509178-44-00 (2025)."},{"key":"2183_CR49","unstructured":"Avian Influenza Vaccinations Begin \u2013 Vaccine to be Offered to Persons at Increased Risk of Infection (Finnish Institute for Health and Welfare (THL), 2025)."},{"key":"2183_CR50","doi-asserted-by":"publisher","unstructured":"Altan, E. et al. Highly pathogenic avian influenza (HPAI) H5N1 virus in Finland in 2021\u20132023: genetic diversity of the viruses and infection kinetics in human dendritic cells. Emerg. Microbes Infect. 14, 2447618 (2025). https:\/\/doi.org\/10.1080\/22221751.2024.2447618","DOI":"10.1080\/22221751.2024.2447618"},{"key":"2183_CR51","unstructured":"Manual for the Laboratory Diagnosis and Virological Surveillance of Influenza (WHO, 2011)."},{"key":"2183_CR52","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.3201\/eid3011.240772","volume":"30","author":"CJ Caceres","year":"2024","unstructured":"Caceres, C. J. et al. Influenza A(H5N1) virus resilience in milk after thermal inactivation. Emerg. Infect. Dis. 30, 2426\u20132429 (2024).","journal-title":"Emerg. Infect. Dis."},{"key":"2183_CR53","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.virusres.2004.02.028","volume":"103","author":"E de Wit","year":"2004","unstructured":"de Wit, E. et al. Efficient generation and growth of influenza virus A\/PR\/8\/34 from eight cDNA fragments. Virus Res. 103, 155\u2013161 (2004).","journal-title":"Virus Res."},{"key":"2183_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9148","volume":"6","author":"J Ping","year":"2015","unstructured":"Ping, J. et al. Development of high-yield influenza A virus vaccine viruses. Nat. Commun. 6, 8148 (2015).","journal-title":"Nat. Commun."},{"key":"2183_CR55","doi-asserted-by":"publisher","DOI":"10.1128\/Spectrum.01131-21","volume":"9","author":"A Solastie","year":"2021","unstructured":"Solastie, A. et al. A highly sensitive and specific SARS-CoV-2 spike- and nucleoprotein-based fluorescent multiplex immunoassay (FMIA) to measure IgG, IgA, and IgM class antibodies. Microbiol. Spectr. 9, e0113121 (2021).","journal-title":"Microbiol. Spectr."},{"key":"2183_CR56","doi-asserted-by":"publisher","first-page":"869990","DOI":"10.3389\/fimmu.2022.869990","volume":"13","author":"A Hurme","year":"2022","unstructured":"Hurme, A. et al. Long-lasting T cell responses in BNT162b2 COVID-19 mRNA vaccinees and COVID-19 convalescent patients. Front. Immunol. 13, 869990 (2022).","journal-title":"Front. Immunol."},{"key":"2183_CR57","doi-asserted-by":"publisher","first-page":"1099246","DOI":"10.3389\/fimmu.2023.1099246","volume":"14","author":"M Belik","year":"2023","unstructured":"Belik, M. et al. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose. Front. Immunol. 14, 1099246 (2023).","journal-title":"Front. Immunol."},{"key":"2183_CR58","doi-asserted-by":"publisher","DOI":"10.1002\/cpz1.934","volume":"3","author":"R da Silva Antunes","year":"2023","unstructured":"da Silva Antunes, R. et al. The MegaPool approach to characterize adaptive CD4+ and CD8+ T cell responses. Curr. Protoc. 3, e934 (2023).","journal-title":"Curr. Protoc."},{"key":"2183_CR59","first-page":"767","volume":"70","author":"D Hobson","year":"1972","unstructured":"Hobson, D., Curry, R. L., Beare, A. S. & Ward-Gardner, A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J. Hyg. 70, 767\u2013777 (1972).","journal-title":"J. Hyg."},{"key":"2183_CR60","doi-asserted-by":"publisher","first-page":"405","DOI":"10.4161\/hv.22908","volume":"9","author":"RJ Cox","year":"2013","unstructured":"Cox, R. J. Correlates of protection to influenza virus, where do we go from here? Hum. Vaccin. Immunother. 9, 405\u2013408 (2013).","journal-title":"Hum. Vaccin. Immunother."}],"container-title":["Nature Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41564-025-02183-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-025-02183-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-025-02183-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T15:01:58Z","timestamp":1767625318000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41564-025-02183-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["2183"],"URL":"https:\/\/doi.org\/10.1038\/s41564-025-02183-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6804016\/v1","asserted-by":"object"}]},"ISSN":["2058-5276"],"issn-type":[{"value":"2058-5276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"8 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A. Sette is a consultant for Alcimed, Arcturus, Darwin Health, Desna Therapeutics, EmerVax, Gilead Sciences, Guggenheim Securities, Link University and RiverVest Venture Partners. The La Jolla Institute for Immunology (LJI) has filed for patent protection for various aspects of T cell epitope and vaccine design work. R.K.S. has acted or acts as a sub-investigator in a COVID-19 study sponsored by Pfizer, a pneumococcal carriage study sponsored by Merck Sharp & Dohme, and influenza, pertussis and meningitis studies sponsored by Sanofi Pasteur, not related to this work. Her current affiliation, Finnish Vaccine Research (FVR), conducts clinical trials and studies sponsored by almost all vaccine providers, not related to this work. H.N. is a member of the National Immunization Technical Advisory Group, THL, Finland, and the chair of the WHO Strategic Advisory Group of Experts. M.M. is a member of the National Immunization Technical Advisory Group, THL, Finland. O.L., A.R., N.E., A.H., A. Solastie, S.V., W.F.R., T.M.B., M.R., R.D.d.V., P.J., E.L., N.I., A.G., T.L., R.H., L.K., M.L., P.K. and I.J. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}